OPTIMIZE — Low-dose Tac+EVR not superior to Tac+MMF in KTRs ≥65 (2026) — Trial Summary
OPTIMIZE — Low-dose Tac+EVR not superior to Tac+MMF in KTRs ≥65 (2026): Randomized clinical trial (OPTIMIZE) in de novo kidney transplant recipients age ≥65 years comparing low-dose tacrolimus + everolimus + prednisolone (TEP) versus standard-dose tacrolimus + mycophenolate mofetil + prednisolone (T
References
- Sanders JF, de Boer SE, Jonker J, et al. Immunosuppression in Older Kidney Transplant Recipients: A Randomized Controlled Trial. J Am Soc Nephrol. 2026;37(4):814-824.